Equities
  • Price (EUR)26.38
  • Today's Change-0.06 / -0.23%
  • Shares traded326.00
  • 1 Year change+15.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

  • Revenue in HUF (TTM)811.42bn
  • Net income in HUF229.13bn
  • Incorporated1923
  • Employees11.60k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RICHTER:BUD since
announced
Transaction
value
BCI Pharma SASDeal completed19 Jun 202419 Jun 2024Deal completed14.53%12.89m
Estetra SADeal completed03 May 202403 May 2024Deal completed15.15%187.69m
Mithra Pharmaceuticals SA-Undisclosed France AssetsDeal completed03 May 202403 May 2024Deal completed15.15%--
Richter-Helm Biologics GmbH & Co KGAnnounced06 Mar 202406 Mar 2024Announced11.25%44.07m
Richter-Helm Biotec GmbH & Co. KGAnnounced06 Mar 202406 Mar 2024Announced11.25%77.94m
Data delayed at least 15 minutes, as of Nov 22 2024 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.